V-safe for Maternal RSV Vaccines
People between 32-36 weeks pregnant who receive the RSV vaccine can register for V-safe. Pfizer’s bivalent RSVpreF vaccine (Abrysvo) is recommended for use during pregnancy.
Registration is quick and easy using your computer, smartphone, or tablet. Get started today!
Vaccine Safety Monitoring Systems
The Vaccine Adverse Event Reporting System (VAERS) serves as the nation’s early warning system to monitor for potential vaccine safety problems. Anyone can report possible health problems to VAERS.
The Vaccine Safety Datalink (VSD) is a collaboration between CDC and 13 health care organizations that conducts active vaccine safety monitoring and research.
V-safe is a safety monitoring system that vaccine recipients can use to share with CDC how they feel after vaccination.
The Clinical Immunization Safety Assessment (CISA) Project is a partnership between CDC and 7 medical research centers that provides expert consultation and conducts clinical research on vaccine-associated health risks.
COVID-19 Vaccine Pregnancy Registry
People who enrolled in V-safe and reported getting a COVID-19 vaccine during pregnancy or within 30 days before their last menstrual period before the pregnancy were invited to participate in the COVID-19 Vaccine Pregnancy Registry.
To receive email updates about this page, enter your email address: